Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 9/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 8/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417243 | 0.81 | PTPN5 (0.45) | AKR1C2MCL1GRIK1PTGER4P2RX1 | |
| SCHEMBL4116157 | 0.81 | PTPN5 (0.44) | AKR1C2MCL1GRIK1PTGER4P2RX1 | |
| SCHEMBL4833538 | 0.75 | AKR1C2 (0.74) | AKR1C2AKR1C1AKR1C3AKR1C4 | |
| SCHEMBL3420563 | 0.75 | CNR1 (0.47) | AKR1C2AKR1C1MCL1GRIK1P2RX1 | |
| SCHEMBL3417230 | 0.73 | TMPRSS4 (0.44) | P2RX1P2RX4P2RX7TMPRSS4PDE2A | |
| SCHEMBL4897243 | 0.70 | CNR2 (0.52) | PDE2A | |
| SCHEMBL6542509 | 0.70 | ALDH1A1 (0.57) | — | |
| SCHEMBL7566604 | 0.70 | GAA (0.61) | — | |
| SCHEMBL6542384 | 0.70 | ALDH1A1 (0.57) | — | |
| SCHEMBL12269600 | 0.69 | ATP1A1 (0.54) | P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | AKR1C2 2738/4885AKR1C1 2609/4885MCL1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.